Plain-English translation of NCT07246460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether ultrasound imaging and blood tests can predict how well guselkumab works for people with Crohn's disease affecting the small intestine. Researchers want to understand if these non-invasive tools can help doctors know early on whether the medication is helping. The study will follow patients for one year, collecting ultrasound images and blood samples at specific time points to track changes.
Currently, doctors struggle to know quickly whether their Crohn's disease treatment is working. This medication is promising, but doctors need better ways to predict which patients will respond well and to monitor progress without relying only on colonoscopies, which are invasive and uncomfortable.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at weeks 0, 12, 24, and 52 over one year. At each visit, you'll have an ultrasound of your bowel performed by a trained specialist and blood drawn for testing. At the start and at the final visit (week 48–52), you'll also have a colonoscopy with small tissue samples taken. The ultrasound scans and blood work help doctors see if the medication is reducing inflammation and thickening in your bowel.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Canada